Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Duloxetine
Drug ID BADD_D00734
Description Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686.[A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.[L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
Indications and Usage **Indicated** for: 1) Management of Major Depressive Disorder.[label] 2) Management of Generalized Anxiety Disorder.[label] 3) Management of diabetic peripheral neuropathy.[label] 4) Management of fibromyalgia.[label] 5) Management of chronic musculoskeletal pain.[label] 6) Management of osteoarthritis of the knee in adults.[L6364] 7) Management of chronic lower back pain in adults.[L6364] 8) Management of stress urinary incontinence in adult women.[L6367] **Off-label** uses include: 1) Management of chemotherapy-induced peripheral neuropathy.[A178603] 2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.[L6370]
Marketing Status approved
ATC Code N06AX21
DrugBank ID DB00476
KEGG ID D07880
MeSH ID D000068736
PubChem ID 60835
TTD Drug ID D01AXB
NDC Product Code 49252-007; 50268-269; 50268-270; 51655-237; 55700-605; 61919-422; 63629-5174; 65841-799; 71205-358; 71205-445; 71205-525; 71205-602; 31722-582; 47335-616; 47335-617; 50268-286; 0228-2892; 60760-559; 70518-1054; 71205-005; 71610-403; 27241-098; 31722-170; 43547-380; 43547-381; 47335-382; 47335-619; 55700-628; 60760-462; 61919-483; 67877-264; 68084-692; 68180-295; 68180-296; 55700-727; 63629-5202; 70518-2630; 76420-236; 31722-169; 47335-383; 47335-618; 49252-009; 50090-6406; 55154-4981; 63629-8051; 63629-8748; 68180-294; 68180-297; 70518-1128; 70518-1139; 70518-3287; 70710-1538; 27241-164; 50268-287; 53002-1494; 60760-461; 65841-801; 67877-265; 70518-2855; 71335-1672; 71335-1964; 46708-278; 68071-2709; 68084-683; 68382-387; 70518-3601; 71335-0402; 71335-2017; 27241-097; 27241-099; 31722-168; 49252-008; 0228-2891; 53002-1561; 68788-7672; 70710-1539; 70771-1344; 70771-1346; 80425-0311; 65977-0035; 46708-280; 47335-381; 50090-6040; 65841-800; 68382-385; 68788-7935; 70710-1537; 70771-1345; 80425-0119; 31722-581; 46708-279; 50090-6281; 50268-288; 55154-4980; 67877-263; 68084-675; 68382-386; 70518-1011; 70518-3177; 31722-583; 43547-379; 45865-813; 50090-4708; 50090-5940; 50268-271; 0228-2890
UNII O5TNM5N07U
Synonyms Duloxetine Hydrochloride | Hydrochloride, Duloxetine | Duloxetine HCl | HCl, Duloxetine | LY 248686 | LY-248686 | LY248686 | Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987 | LY 227942 | LY-227942 | LY227942 | Duloxetine | N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide | N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine | Duloxetine, (+)-isomer | Cymbalta
Chemical Information
Molecular Formula C18H19NOS
CAS Registry Number 116539-59-4
SMILES CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyschezia07.02.03.0050.000027%Not Available
Systemic inflammatory response syndrome24.06.03.008; 10.02.01.008; 08.01.05.0050.000053%Not Available
Haemodynamic instability24.03.02.0060.000040%Not Available
Ear discomfort04.03.01.0050.000085%Not Available
Musculoskeletal stiffness15.03.05.0270.000389%Not Available
Epigastric discomfort07.01.02.0040.000072%Not Available
Alcohol withdrawal syndrome19.07.06.005; 08.06.02.0020.000027%Not Available
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.000818%Not Available
Depressive symptom19.15.02.0030.000197%Not Available
Affect lability19.04.01.0010.035836%Not Available
Skin burning sensation17.02.06.009; 23.03.03.0210.000131%Not Available
Cerebral disorder17.02.10.0170.000189%Not Available
Phonophobia19.06.03.003; 04.03.01.0080.000040%Not Available
Dysphemia19.19.03.005; 17.02.08.0100.000144%Not Available
Parkinsonian gait17.01.05.005; 08.01.02.0050.000027%Not Available
Food craving19.09.01.010; 14.03.01.0090.000104%Not Available
Gynaecological examination abnormal13.15.01.021--Not Available
Colitis microscopic07.08.01.0110.000333%Not Available
Temperature intolerance08.01.09.0220.000027%Not Available
Urine odour abnormal20.02.01.0200.000040%Not Available
Daydreaming19.21.02.0050.000059%Not Available
Hypoaesthesia oral07.05.05.003; 17.02.06.0210.000125%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000157%Not Available
Anxiety disorder19.06.01.0020.000040%Not Available
Bipolar disorder19.16.01.0030.000112%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.000386%
Major depression19.15.01.0030.000192%Not Available
Dyslipidaemia14.08.04.015--Not Available
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.0070.000072%Not Available
Restless legs syndrome17.02.07.008; 15.05.03.0120.000557%Not Available
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 21 Pages